Medical oncology

Our Medical Oncology Services provide clinical expertise, compassionate care and support to patients and their loved ones. Our multidisciplinary care is delivered through the Bendat Family Comprehensive Care Centre, located at St John of God Subiaco Hospital.

Cancer is the leading cause of death in Australia, with about 1 in 2 Australian men and 1 in 3 Australian women will be diagnosed with cancer in their life.
Clinical trials play an essential role in discovering new and more effective treatments for cancer.
Outstanding research-based health care is provided to all participants involved in clinical trials and we offer comprehensive and integrated evidence-based treatment options.

This unit conducts commercial clinical trials in Oncology. Areas of focus include:

Gynaecological Cancers
Breast Cancer
Pancreatic/Upper Gastrointestinal Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Brain Cancer
Melanoma

Trials range from early to late phase; with the unit ensuring a critical focus on patient safety. This commitment to research enables us to deliver the best treatments and practices to our patients.

St John of God Subiaco Hospital

Head of Department, Cancer Services
Dr Andrew Dean

Head of Palliative Care Services
Dr Derek Eng

Medical Registrar
Dr Shaun Ong
Dr Janelle Prunster

Project Manager – Clinical Trials Development
Dr Jo Youd

Research Data Scientist
Andrew Mews

Please see Oncology Clinical Trial Unit for all other key staff.

Ledermann, J. A., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Weberpals, J. I., Clamp, A. R., Scambia, G., Leary, A., Holloway, R. W., Gancedo, M. A., Fong, P. C., Goh, J. C., O’Malley, D. M., Armstrong, D. K., Banerjee, S., García-Donas, J., Swisher, E. M., … Coleman, R. L. (2020). Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. The Lancet. Oncology, 21 (5), 710–722. doi. org/10.1016/S1470-2045 (20)30061-9

Pfisterer, J., Shannon, C. M., Baumann, K., Rau, J., Harter, P., Joly, F., Sehouli, J., Canzler, U., Schmalfeldt, B., Dean, A. P., Hein, A., Zeimet, A. G., Hanker, L. C., Petit, T., Marmé, F., El-Balat, A., Glasspool, R., de Gregorio, N., Mahner, S., Meniawy, T. M., … AGO-OVAR 2.21/ENGOT-ov 18 Investigators (2020). Bevacizumab and platinumbased combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. The Lancet. Oncology, 21 (5), 699–709. doi.org/10.1016/S1470-2045 (20)30142-X

Clamp, A.R., James, E.C., McNeish, I.A., Dean, A.et al. (2019) Weekly dose-dense chemotherapy in firstline epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. The Lancet. 394 (10214):2084-2095. doi:10.1016/S0140-6736(19)32259-7